A TCF4-Dependent Gene Regulatory Network Confers Resistance to Immunotherapy in Melanoma

Targeting TCF4 genetically or pharmacologically, using a bromodomain inhibitor, increased immunogenicity and sensitivity of mesenchymal-like cells toi mmune checkpoint blockade and targeted therapy.